Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.80 |
| ▸ | NPC1 | O15118 | 2/20 | 0.80 |
| ▸ | MAPT | P10636 | 1/20 | 0.80 |
| ▸ | RAB9A | P51151 | 1/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.80 |
| ▸ | CASP3 | P42574 | 1/20 | 0.72 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4300016 | 0.98 | ALDH1A1 (0.78) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4296357 | 0.93 | ALDH1A1 (0.91) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL9178262 | 0.89 | ALDH1A1 (1.00) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL12857935 | 0.84 | CASP3 (0.90) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL12857988 | 0.84 | CASP3 (1.00) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL6265770 | 0.82 | ALDH1A1 (1.00) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL12857936 | 0.79 | CASP3 (0.78) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL28656982 | 0.79 | PTPN1 (0.89) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL125695 | 0.79 | PTPN1 (0.89) | ALDH1A1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL12284611 | 0.78 | PTPN1 (0.69) | ALDH1A1NPC1HPGDKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253709-A1 | SYNTHESIS, TELOMERASE INHIBITION AND CYTOTOXIC STUDIES ON 2,7-DISUBSTITUTED ANTHRAQUINONE DERIVATIVES | TERT, NAT10, POT1 | ALDH1A1 481/4885NPC1 2511/4885MAPT 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.